Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice

Journal of Cardiovascular Pharmacology

Volumn 55, Issue 2, 2010, Pages 117-122

  Van Tassell, Benjamin W ^a   Varma, Amit ^a   Salloum, Fadi N ^a   Das, Anindita ^a   Seropian, Ignacio M ^a   Toldo, Stefano ^a   Smithson, Lisa ^a   Hoke, Nicholas N ^a   Chau, Vinh Q ^a   Robati, Roshanak ^a   Abbate, Antonio ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Cardiac remodeling; IL 1 Trap; Inflammation; Interleukin 1; Myocardial infarction; Rilonacept

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; RILONACEPT; SODIUM CHLORIDE; HYBRID PROTEIN;

ACUTE HEART INFARCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; IN VITRO STUDY; MALE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL DEATH; COMPARATIVE STUDY; DISEASE MODEL; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL DEATH; CELLS, CULTURED; DISEASE MODELS, ANIMAL; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MICE; MICE, INBRED ICR; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 77649290682     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181c87e53     Document Type: Article

References (33)

1. National Heart, Lung, and Blood Institute. Morbidity and Mortality: 2007 Chart Book on Cardiovascular and Lung Diseases. Bethesda, MD: National Institutes of Health; 2007.
2. Herskowitz A, Choi S, Ansari A, et al. Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol. 1995;146:419-428.
3. Dewald O, Ren G, Duerr GH, et al. Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. Am J Pathol. 2004;164:665-677.
4. Testa M, Yeh M, Lee P, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 1996;28:964-971.
5. Abbate A, Bussani R, Amin MS, et al. Acute myocardial infarction and heart failure: role of apoptosis. Int J Biochem Cell Biol. 2006;38: 1834-1840.
6. Dinarello CA. Interleukin-1. Cytokine Growth Factor Rev. 1997;8:253-265.
7. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454.
8. Di Iorio A, Ferrucci L, Sparvieri E, et al. Serum IL-1beta levels in health and disease: a population-based study. The InCHIANTI study. Cytokine. 2003;22:198-205.
9. Bujak M, Dobaczewski M, Chatila K, et al. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol. 2008;173:57-67.
10. Abbate A, Salloum FN, Vecile E, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental myocardial infarction. Circulation. 2008;117:2670-2683.
11. Hwang MW, Matsumori A, Furukawa Y, et al. Neutralization of interleukin-1 in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J Am Coll Cardiol. 2001;38: 1546-1553.
12. Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multicomponent, high-affinity blockers of cytokine action. Nat Med. 2003;9: 47-52.
13. Schiller NB, Shah PM, Crawford M, et al; for the American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358-367.
14. Tei C, Ling LH, Hodge DO, et al. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function: a study in normal and dilated cardiomyopathy. Am J Cardiol. 1995;26:357-366.
15. Abbate A, Bussani R, Biondi-Zoccai GG, et al. Infarct-related artery occlusion, tissue markers of ischaemia, and increased apoptosis in the peri-infarct viable myocardium. Eur Heart J. 2005;26:2039-2045.
16. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis: essential role of nitric oxide signaling. J Biol Chem. 2005;280:12944-12955.
17. Cohn JN, Ferrari R, Sharpe N; International Forum on Cardiac Remodeling. Cardiac Remodeling-concepts and clinical implications: a consensus paper from international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35:569-582.
18. Nian M, Lee P, Khaper N, et al. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004;94:1543-1553.
19. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction-experimental observations and clinical implications. Circulation. 1990;81:1161-1172.
20. Sam F, Sawyer DB, Chang DL, et al. Progressive left ventricular remodeling and apoptosis late after myocardial infarction in mouse heart. Am J Physiol Heart Circ Physiol. 2000;279:H422-H428.
21. MacLellan WR, Schenider MD. Death by design. Programmed cell death in cardiovascular biology and disease. Circ Res. 1997;81:137-144.
22. Guillen I, Blanes M, Gomez-Lechon MJ, et al. Cytokine signaling during myocardial infarction: sequential appearance of IL-1 beta and IL-6. Am J Physiol. 1995;269:R229-R235.
23. Carlson DL, Maass DL, White J, et al. Caspase inhibition reduces cardiac myocyte dyshomeostasis and improves cardiac contractile function after major burn injury. J Appl Physiol. 2007;103:323-330.
24. Maass DL, White J, Horton JW. Nitric oxide donors alter cardiomyocyte cytokine secretion and cardiac function. Crit Care Med. 2005;33: 2794-2803.
25. Church LD, McDermott MF. Rilonacept in cryopyrin-associated periodic syndromes: the beginning of longer-acting interleukin-1 antagonism. Nat Clin Pract Rheumatol. 2009;5:14-15.
26. Available at: www.regeneron.com/il-1trap.html. Accessed July 23, 2009.
27. Zell R, Geck P, Werdan K, et al. TNF-a and IL-1a inhibit both pyruvate dehydrogenase activity and mitochondrial function in cardiomyocytes: evidence for primary impairment of mitochondrial function. Moll Cell Biochem. 1997;177:61-67.
28. Isoda K, Kamezawa Y, Tada N, et al. Myocardial hypertrophy in transgenic mice overexpressing human interleukin 1a. J Card Failure. 2001;7: 355-364.
29. Crossman DC, Morton AC, Gunn JP, et al. Investigation of the effect of interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study). Trials. 2008;9:8.
30. Available at: www.clinicaltrials.gov/ct2/show/NCT00789724. Accessed September 14, 2009.
31. Klein B, Brailly H. Cytokine-binding proteins: stimulating antagonists. Immunol Today. 1995;16:216-220.
32. Vandervelde S, van Amerongen MJ, Tio RA, et al. Increased inflammatory response and neorevascularization in reperfused vs nonreperfused murine myocardial infarction. Cardiovasc Pathol. 2006;16:83-90.
33. Abbate A, Kontos MC, Biondi-Zoccai GGL. No-reflow: the next challenge in treatment of ST-elevation acute myocardial infarction. Eur Heart J. 2008;29:1795-1797.